STARCOIN GROUP LIMITED
星 太 鏈 集 團 有 限 公 司

(Formerly known as Innovative Pharmaceutical Biotech Limited 領航醫藥及生物科技有限公司)
(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)
(Stock Code: 399)

DECISION OF THE LISTING REVIEW COMMITTEE AND APPLICATION FOR THE JUDICIAL REVIEW

This announcement is made by Starcoin Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules (the "**Listing Rules**") Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements (the "**Announcements**") of the Company dated 17 November 2025, 24 November 2025, and 2 February 2026 in relation to the decision of the Stock Exchange that the Company has failed to maintain a sufficient level of operations as required under Rule 13.24 of the Listing Rules (the "**Decision**"), the Company's review application of the Decision to the Listing Committee, the Decision of the Listing Committee (the "**LD Decision**") and the request to review of the LD Decision on Rule 13.24 to the Listing Review Committee (the "**LRC Review Application**") (the "**Announcements**"). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meaning as those defined in the Announcements.

DECISION OF LISTING REVIEW COMMITTEE

The Listing Review Committee conducted a hearing ("**Hearing**") of the LRC Review Application on 31 March 2026. On 28 April 2026, the Company received a letter (the "**Letter**") from the Listing Review Committee notifying that having taken into account the submissions of the Company and the Listing Division, including the submissions of the Company at the Hearing, the Listing Review Committee decided to uphold the LC Decision to suspend trading in the Company's shares under Rule 6.01(3) on the ground that the Company had failed maintain a sufficient level of operations and assets of sufficient value to support its operations to warrant the continued listing of its shares, in compliance with Rule 13.24 ("**LRC Decision**").

APPLICATION FOR JUDICIAL REVIEW

The Company has secured an interim interim injunction order against the implementation of the LRC Decision, effective until next Tuesday, and will pursuant to such order formally file an application for leave to apply for judicial review against the LRC Decision and to apply for interim injunction relief. A hearing is fixed to hear the Company's application for leave to apply for judicial review and for interim injunction relief. The trading in the shares remains active.

Further announcement(s) will be made by the Company as and when appropriate and in accordance with the requirements of the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Starcoin Group Limited
Yeung Yung
Chairman

Hong Kong, 29 April 2026

As at the date of this announcement, the Board comprises, Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director) Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkang, Tim (independent non-executive Director) and Ms. Sun Sizheng (independent non-executive Director).

Please also refer to the published version of this announcement on the Company's website: www.starcoingroup.com and www.irasia.com/listco/hk/starcoingroup.